IMA — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-05

• The following table summarizes our results of operations for the three months ended June 30, 2026 and 2025 (in thousands):

• We did not have license revenue for either of the three months ended June 30, 2026 or 2025. Following the Non-OX40 Divestiture, we no longer generate revenue under license and collaboration agreements.

• The following table summarizes our results of operations for the six months ended June 30, 2026 and 2025 (in thousands):

• License revenue for the six months ended June 30, 2025 related to non-OX40 programs. Following the Non-OX40 Divestiture, we no longer generate revenue under license and collaboration agreements.

• The following table sets forth our research and development expenses (in thousands):

Text removed vs the prior filing · source: 10-Q · 2026-05-07

• Comparison of the Three Months Ended March 31, 2026 and 2025

• The following table summarizes our results of operations for the three months ended March 31, 2026 and 2025 (in thousands):

• License revenue for the three months ended March 31, 2025 related to non-OX40 programs. Following the Non-OX40 Divestiture, we no longer generate revenue under license and collaboration agreements.

• Since inception, we have devoted substantially all of our resources to advancing the development of our portfolio of programs, organizing and staffing, business planning, raising capital, and providing general and administrative support for these operations. We have incurred recurring losses and neg…

• As of March 31, 2026, we had cash, cash equivalents and marketable securities of $117.2 million. In April 2026, we received gross proceeds of $30.0 million from the Private Placement.

Text added vs the prior filing · source: 10-Q · 2026-08-05

• adverse events and safety information from other clinical trials of other product candidates also targeting OX40;

• the cost of clinical trials of olevaprubart or any future product candidates may be greater than we anticipate and we may elect not to cover the costs;

• the supply or quality of olevaprubart or any future product candidates or other materials necessary to conduct clinical trials of olevaprubart or any future product candidates may be insufficient or inadequate;

• regulators may revise the requirements for approving olevaprubart or any future product candidates, or such requirements may not be as we anticipate; and

• Sarcoma have been reported. To date, a causal association between the therapies targeting the pathway and the events has not been established.

Text removed vs the prior filing · source: 10-Q · 2026-05-07

• the cost of clinical trials of IMG-007 or any future product candidates may be greater than we anticipate and we may elect not to cover the costs;

• the supply or quality of IMG-007 or any future product candidates or other materials necessary to conduct clinical trials of IMG-007 or any future product candidates may be insufficient or inadequate;

• regulators may revise the requirements for approving IMG-007 or any future product candidates, or such requirements may not be as we anticipate; and

• There may be undesirable side effects and adverse events associated with IMG-007 or any future product candidates. Undesirable side effects or adverse events that may be caused by IMG-007 or any future product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical t…

• While the data reported to date from our Phase 1 and Phase 2a clinical trials indicate that IMG-007 was generally well tolerated, there remains a risk that clinical trial results could reveal high and unacceptable severity and prevalence of previously unreported side effects or unexpected characteri…